Celldex shares slip 15% as safety concerns cloud skin drug trial win

Celldex Therapeutics' shares fell 15% after the company announced a positive outcome in a skin drug trial, but safety concerns have cast a shadow over the results. The company's experimental treatment showed significant improvement in patients with a specific skin condition, but some participants experienced adverse effects. This has raised questions about the drug's long-term safety and efficacy. As a result, investors are reevaluating their expectations for the company's future prospects.

Why it matters

Celldex Therapeutics' experimental skin drug trial has raised safety concerns, which is likely to negatively impact the company's stock price. The concerns may lead to a decrease in investor confidence and a subsequent decline in the stock price.

Market impact

Transmission channels

Likely winners & losers

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to Economic Times. For information only — not financial advice.